# Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer

> **NCT02322593** · PHASE3 · COMPLETED · sponsor: **Taiho Pharmaceutical Co., Ltd.** · enrollment: 711 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** TAS-118 plus Oxaliplatin
- **DRUG:** S-1 plus Cisplatin

## Key facts

- **NCT ID:** NCT02322593
- **Lead sponsor:** Taiho Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2019-02
- **Final completion:** 2020-05
- **Target enrollment:** 711 (ACTUAL)
- **Last updated:** 2021-12-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02322593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02322593, "Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02322593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*